# International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

> **NCT02065765** · — · APPROVED_FOR_MARKETING · sponsor: **Eli Lilly and Company**

## Conditions studied

- Metastatic Gastric Cancer
- Metastatic Adenocarcinoma of the Gastroesophageal Junction

## Interventions

- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT02065765
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065765, "International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02065765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*